ENZO BIOCHEM INC
NT 10-Q, 1999-12-16
MEDICAL LABORATORIES
Previous: FMR CORP, SC 13G/A, 1999-12-16
Next: ENZO BIOCHEM INC, 10-Q, 1999-12-16




<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                   FORM 12B-25

                                                   Commission File Number 1-9974

                           NOTIFICATION OF LATE FILING

      (Check One): |_| Form 10-K   |_| Form 11-K   |_| Form 20-F   |X| Form 10-Q
                   |_| Form N-SAR

         For Period Ended: _____________________________________________________

         |_| Transition Report on Form 10-K
         |_| Transition Report on Form 20-F
         |_| Transition Report on Form 11-K
         |_| Transition Report on Form 10-Q
         |_| Transition Report on Form N-SAR

         For the Transition Period Ended:_______________________________________

         Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.

         If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:


                                     PART I
                             REGISTRANT INFORMATION

Full name of registrant            ENZO BIOCHEM, INC.
                         -------------------------------------------------------
Former name if applicable

- --------------------------------------------------------------------------------
Address of principal executive office (STREET AND NUMBER)

                                60 Executive Boulevard
- --------------------------------------------------------------------------------
City, state and zip code        Farmingdale, New York 11735
                         -------------------------------------------------------


                                     PART II
                             RULE 12B-25 (B) AND (C)

         If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)




                                       1
<PAGE>

           (a)  The reasons described in reasonable detail in Part III of this
                form could not be eliminated without unreasonable effort or
                expense;
           (b)  The subject annual report, semi-annual report, transition report
                on Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will
                be filed on or before the 15th calendar day
   |X|          following the prescribed due date; or the subject quarterly
                report or transition report on Form 10-Q, or portion thereof
                will be filed on or before the fifth calendar day following the
                prescribed due date; and
           (c)  The accountant's statement or other exhibit required by Rule
                12b-25(c) has been attached if applicable.

                                    PART III
                                    NARRATIVE

     State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F,
10-Q, N-SAR or the transition report portion thereof could not be filed within
the prescribed time period. (Attach extra sheets if needed.)

     The inability of the Registrant to file timely the Form 10-Q was due to the
Registrant's inability to complete its review of the interim financial
information to be included in the Form 10-Q.

                                     PART IV
                                OTHER INFORMATION

     (1) Name and telephone number of person to contact in regard to this
notification:

          Shahram K. Rabbani                        (516)       755-5500
- --------------------------------------------------------------------------------
                  (Name)                  (Area Code)  (Telephone Number)

     (2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
                                                              |X| Yes     |_| No

     (3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
                                                              |_| Yes     |X| No

     If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.

                               ENZO BIOCHEM, INC.
- --------------------------------------------------------------------------------
                  (Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.



                                       2
<PAGE>

Date      December 16, 1999                  By        /s/ Shahram K. Rabbani
     -----------------------------                -----------------------------
                                                       Shahram K. Rabbani
                                                       Chief Operating Officer

                                        3


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission